The findings from two studies published in JAMA show the benefits of initial disease-modifying therapy and nonmyeloablative haematopoietic stem cell transplantation in delaying conversion to secondary progressive multiple sclerosis.
Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis, suggest the results of an observational cohort study published in JAMA Neurology.
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation can induce long-term remission for patients with relapsing–remitting multiple sclerosis, show findings from the HALT-MS trial.
Phase 3 trial results have shown the benefits of ocrelizumab for reducing disability progression in patients with primary progressive multiple sclerosis and disease activity in patients with the relapsing–remitting disease subtype.
Amiselimod shows potential for the treatment of relapsing–remitting multiple sclerosis, without the cardiac side effects associated with other sphingosine 1-phosphate 1 receptor modulators, phase II study findings show.
The 11-year follow-up results of the BENEFIT trial emphasize the importance of initiating treatment early in individuals exhibiting the signs of multiple sclerosis onset, say researchers who observed long-lasting improvements in disease progression and disability.
Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.